Journal
NATURE MEDICINE
Volume 12, Issue 6, Pages 688-692Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm1416
Keywords
-
Ask authors/readers for more resources
Despite a more than 20-year experience of therapeutic benefit, the relevant molecular and cellular targets of intravenous immunoglobulin ( IVIg) in autoimmune disease remain unclear. Contrary to the prevailing theories of IVIg action in autoimmunity, we show that IVIg drives signaling through activating Fc gamma receptors ( Fc gamma R) in the amelioration of mouse immune thrombocytopenic purpura ( ITP). The actual administration of IVIg was unnecessary because as few as 105 IVIg-treated cells could, upon adoptive transfer, ameliorate ITP. IVIg did not interact with the inhibitory Fc gamma RIIB on the initiator cell, although Fc gamma RIIB does have a role in the late phase of IVIg action. Notably, only IVIg-treated CD11c(+) dendritic cells could mediate these effects. We hypothesize that IVIg forms soluble immune complexes in vivo that prime dendritic-cell regulatory activity. In conclusion, the clinical effects of IVIg in ameliorating ITP seem to involve the acute interaction of IVIg with activating Fc gamma R on dendritic cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available